These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 9562516)
1. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Isomäki P; Punnonen J Ann Med; 1997 Dec; 29(6):499-507. PubMed ID: 9562516 [TBL] [Abstract][Full Text] [Related]
2. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Yin Z; Siegert S; Neure L; Grolms M; Liu L; Eggens U; Radbruch A; Braun J; Sieper J Rheumatology (Oxford); 1999 Nov; 38(11):1058-67. PubMed ID: 10556256 [TBL] [Abstract][Full Text] [Related]
3. Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium. Woods JM; Katschke KJ; Tokuhira M; Kurata H; Arai KI; Campbell PL; Koch AE J Immunol; 2000 Sep; 165(5):2755-63. PubMed ID: 10946307 [TBL] [Abstract][Full Text] [Related]
4. Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium. Morita Y; Yamamura M; Kawashima M; Aita T; Harada S; Okamoto H; Inoue H; Makino H Rheumatol Int; 2001 Feb; 20(2):49-54. PubMed ID: 11269532 [TBL] [Abstract][Full Text] [Related]
7. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Woolley DE; Tetlow LC Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391 [TBL] [Abstract][Full Text] [Related]
8. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663 [TBL] [Abstract][Full Text] [Related]
9. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Isomäki P; Luukkainen R; Toivanen P; Punnonen J Arthritis Rheum; 1996 Oct; 39(10):1693-702. PubMed ID: 8843860 [TBL] [Abstract][Full Text] [Related]
10. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. Sugiyama E; Kuroda A; Taki H; Ikemoto M; Hori T; Yamashita N; Maruyama M; Kobayashi M J Rheumatol; 1995 Nov; 22(11):2020-6. PubMed ID: 8596138 [TBL] [Abstract][Full Text] [Related]
11. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Jüngel A; Distler JH; Kurowska-Stolarska M; Seemayer CA; Seibl R; Forster A; Michel BA; Gay RE; Emmrich F; Gay S; Distler O Arthritis Rheum; 2004 May; 50(5):1468-76. PubMed ID: 15146416 [TBL] [Abstract][Full Text] [Related]
12. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Butler DM; Maini RN; Feldmann M; Brennan FM Eur Cytokine Netw; 1995; 6(4):225-30. PubMed ID: 8789287 [TBL] [Abstract][Full Text] [Related]
13. [Rheumatoid arthritis and cytokines]. Kaneko S; Kondo Y; Yokosawa M; Sumida T Nihon Rinsho; 2016 Jun; 74(6):913-8. PubMed ID: 27311178 [TBL] [Abstract][Full Text] [Related]
14. Effects of pro- and anti-inflammatory cytokines and nitric oxide donors on hyaluronic acid synthesis by synovial cells from patients with rheumatoid arthritis. Chenevier-Gobeaux C; Morin-Robinet S; Lemarechal H; Poiraudeau S; Ekindjian JC; Borderie D Clin Sci (Lond); 2004 Sep; 107(3):291-6. PubMed ID: 15149282 [TBL] [Abstract][Full Text] [Related]
15. Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway. Liu FL; Chen CH; Chu SJ; Chen JH; Lai JH; Sytwu HK; Chang DM Rheumatology (Oxford); 2007 Aug; 46(8):1266-73. PubMed ID: 17569750 [TBL] [Abstract][Full Text] [Related]
16. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Feldmann M; Maini RN Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034 [TBL] [Abstract][Full Text] [Related]
17. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. Chabaud M; Page G; Miossec P J Immunol; 2001 Nov; 167(10):6015-20. PubMed ID: 11698482 [TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Lories RJ; Derese I; Ceuppens JL; Luyten FP Arthritis Rheum; 2003 Oct; 48(10):2807-18. PubMed ID: 14558086 [TBL] [Abstract][Full Text] [Related]
19. Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Harigai M; Hara M; Yoshimura T; Leonard EJ; Inoue K; Kashiwazaki S Clin Immunol Immunopathol; 1993 Oct; 69(1):83-91. PubMed ID: 8403545 [TBL] [Abstract][Full Text] [Related]
20. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor. Ernestam S; af Klint E; Catrina AI; Sundberg E; Engström M; Klareskog L; Ulfgren AK Arthritis Res Ther; 2006; 8(1):R18. PubMed ID: 16507118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]